NALBUPHINE HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for nalbuphine hydrochloride and what is the scope of patent protection?
Nalbuphine hydrochloride
is the generic ingredient in three branded drugs marketed by Abraxis Pharm, Abbott, Abbvie, Dr Reddys, Hospira, Igi Labs Inc, Rising, Somerset Theraps Llc, and Endo Operations, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.There are five drug master file entries for nalbuphine hydrochloride. Five suppliers are listed for this compound.
Summary for NALBUPHINE HYDROCHLORIDE
US Patents: | 0 |
Tradenames: | 3 |
Applicants: | 9 |
NDAs: | 20 |
Drug Master File Entries: | 5 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 17 |
Clinical Trials: | 109 |
Patent Applications: | 970 |
What excipients (inactive ingredients) are in NALBUPHINE HYDROCHLORIDE? | NALBUPHINE HYDROCHLORIDE excipients list |
DailyMed Link: | NALBUPHINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for NALBUPHINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Yongtao Sun | Phase 4 |
Kasr El Aini Hospital | N/A |
Chulalongkorn University | N/A |
Pharmacology for NALBUPHINE HYDROCHLORIDE
Drug Class | Opioid Agonist/Antagonist |
Mechanism of Action | Competitive Opioid Antagonists Partial Opioid Agonists |
Medical Subject Heading (MeSH) Categories for NALBUPHINE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for NALBUPHINE HYDROCHLORIDE
US Patents and Regulatory Information for NALBUPHINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Igi Labs Inc | NALBUPHINE HYDROCHLORIDE | nalbuphine hydrochloride | INJECTABLE;INJECTION | 072072-001 | Apr 10, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Somerset Theraps Llc | NALBUPHINE HYDROCHLORIDE | nalbuphine hydrochloride | INJECTABLE;INJECTION | 216049-002 | Sep 19, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Igi Labs Inc | NALBUPHINE HYDROCHLORIDE | nalbuphine hydrochloride | INJECTABLE;INJECTION | 072071-001 | Apr 10, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Igi Labs Inc | NALBUPHINE HYDROCHLORIDE | nalbuphine hydrochloride | INJECTABLE;INJECTION | 072074-001 | Apr 10, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Igi Labs Inc | NALBUPHINE HYDROCHLORIDE | nalbuphine hydrochloride | INJECTABLE;INJECTION | 072075-001 | Apr 10, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.